Vaccination Scheme and Clinical Monitoring

After informed consent was signed, patients were selected, and the inclusion and exclusion criteria were confirmed. The patients were randomly assigned to receive concomitant with NAC autologous DCs or only NAC. The vaccination schedule of patients with DCs consisted of ~2 × 10⁷ cells per dose for a total of six doses. Between each session of A/C chemotherapy (scheduled every 21 days), we apply two doses of cells, one per week. The cells were injected intradermally near the tumor lesson in the affected breast. During each dose, patients were monitored in the hospital for adverse effects for 3–4 h; after that, a daily check was done to evaluate the appearance of adverse effects (Figure 1C).